Welcome to Oncimmune

OncImmune was founded in 2003 to commercialise technology developed in the laboratories of Professor John Robertson, a professor of surgery at the University of Nottingham, England. Research continues in the laboratory of Professor Roberston, while development of products is funded through OncImmune, Ltd.

Patients

Understanding EarlyCDT

EarlyCDT uses a highly reliable technology of testing to identify early-stage cancer. Learn More>


EarlyCDT—Lung Brochure

Our informative booklet of the features and benefits of EarlyCDT for Lung cancer. Download>


What is my 5-year risk?

Learn More>


EarlyCDT—Breast Brochure

Our informative booklet of the features and benefits of EarlyCDT for Breast cancer. Download>

 

Providers

Who Benefits from EarlyCDT

EarlyCDT gives the advantage of earlier detection to patients at increased risk of developing certain cancers. Learn More>


Technology

Autoantibodies specific to cancer-related antigens are key to an early detection success. Learn More>


What is the 5-year risk?

Learn More>


Insurance Reimbursement

EarlyCDT is self-pay, physician–directed test. Learn More>

 

Oncimmune

Investors

The Future of EarlyCDT

Ongoing research holds great promise for an expanding line of EarlyCDT products. Learn More>

 

Research Partners

Understanding EarlyCDT

Oncimmune has attracted the interest and participation of leading cancer researchers. Learn More>

 

Press Statements

Oncimmune Testing and Mammography

Simple Reassurance for Women at Increased Risk for Breast Cancer. 03/09/08 Read More »

New Website

Oncimmune have launced their new website. 29/08/08 Read More »